pubmed.ncbi.nlm.nih.gov

Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth - PubMed

Review

Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth

John J Lehman et al. Heart Fail Rev. 2002 Apr.

Abstract

Studies in a variety of mammalian species, including humans, have demonstrated a reduction in fatty acid oxidation (FAO) and increased glucose utilization in pathologic cardiac hypertrophy, consistent with reinduction of the fetal energy metabolic program. This review describes results of recent molecular studies aimed at delineating the gene regulatory events which facilitate myocardial energy substrate switches during hypertrophic growth of the heart. Studies aimed at the characterization of transcriptional control mechanisms governing FAO enzyme gene expression in the cardiac myocyte have defined a central role for the fatty acid-activated nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR(alpha)). Cardiac FAO enzyme gene expression was shown to be coordinately downregulated in murine models of ventricular pressure overload, consistent with the energy substrate switch away from fatty acid utilization in the hypertrophied heart. Nuclear protein levels of PPAR(alpha) decline in the ventricle in response to pressure overload, while several Sp and nuclear receptor transcription factors are induced to fetal levels, consistent with their binding to DNA as transcriptional repressors of rate-limiting FAO enzyme genes with hypertrophy. Knowledge of key components of this transcriptional regulatory pathway will allow for the development of genetic engineering strategies in mice that will modulate fatty acid oxidative flux and assist in defining whether energy metabolic derangements play a primary role in the development of pathologic cardiac hypertrophy and eventual progression to heart failure.

PubMed Disclaimer

Cited by

Cardiac complications in inherited mitochondrial diseases.
Behjati M, Sabri MR, Etemadi Far M, Nejati M. Behjati M, et al. Heart Fail Rev. 2021 Mar;26(2):391-403. doi: 10.1007/s10741-020-10009-1. Heart Fail Rev. 2021. PMID: 32728985 Review.
Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice.
Elrod JW, Wong R, Mishra S, Vagnozzi RJ, Sakthievel B, Goonasekera SA, Karch J, Gabel S, Farber J, Force T, Brown JH, Murphy E, Molkentin JD. Elrod JW, et al. J Clin Invest. 2010 Oct;120(10):3680-7. doi: 10.1172/JCI43171. Epub 2010 Sep 20. J Clin Invest. 2010. PMID: 20890047 Free PMC article.
Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective.
Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Wolff AA, et al. Heart Fail Rev. 2002 Apr;7(2):187-203. doi: 10.1023/a:1015384710373. Heart Fail Rev. 2002. PMID: 11988642 Review.
Measuring regional changes in the diastolic deformation of the left ventricle of SHR rats using microPET technology and hyperelastic warping.
Veress AI, Weiss JA, Huesman RH, Reutter BW, Taylor SE, Sitek A, Feng B, Yang Y, Gullberg GT. Veress AI, et al. Ann Biomed Eng. 2008 Jul;36(7):1104-17. doi: 10.1007/s10439-008-9497-9. Epub 2008 Apr 24. Ann Biomed Eng. 2008. PMID: 18437574 Free PMC article.
Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice.
Chang CS, Tsai PJ, Sung JM, Chen JY, Ho LC, Pandya K, Maeda N, Tsai YS. Chang CS, et al. Am J Pathol. 2014 Feb;184(2):442-53. doi: 10.1016/j.ajpath.2013.10.020. Epub 2013 Nov 26. Am J Pathol. 2014. PMID: 24287404 Free PMC article.

References

1. Science. 1999 Nov 12;286(5443):1368-71 - PubMed
1. Mol Cell Biol. 2000 Mar;20(5):1868-76 - PubMed
1. Prostaglandins Leukot Essent Fatty Acids. 1999 May-Jun;60(5-6):339-43 - PubMed
1. Science. 1999 Mar 5;283(5407):1482-8 - PubMed
1. Curr Probl Cardiol. 1994 Feb;19(2):59-113 - PubMed

Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth - PubMed